The Norwegian Cancer Society (NCS) has recently organized a investment fund for Norwegian companies with a focus on developing novel cancer therapies. With the promising development of VB10.16, Vaccibody’s therapeutic vaccine against HPV induced precancerous lesions, NCS has decided to place their first investment in Vaccibody. For publication in Norwegian, see Dagens Næringsliv April 24th.
“We are very pleased to see that Vaccibody has fulfilled all investment criteria demanded by NCS and is very proud that we are the first company they are investing in. This investment is an important step toward the financing of our first-in-man study” CEO Ole Henrik Brekke says in comment.